Skip to main content

Obesity-Related Diseases and Syndromes: Insulin Resistance, Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Cardiovascular Disease, and Metabolic Syndrome

  • Chapter
  • First Online:
Obesity

Abstract

Fat accumulates within the body of a person who is overweight or obese until many small physiological changes accumulate to a tipping point where adipose tissue becomes “sick.” Adisopathy or “sick fat” leads to a host of other obesity-related diseases. In this chapter the development of adisopathy is discussed in detail with an emphasis on insulin resistance and the role of mitochondria, hormones, inflammatory markers and leptin. This chapter describes the mechanisms of disease for prediabetes and type 2 diabetes and explores the concept of metabolic syndrome. It also explains the pathophysiology of obesity as it relates to non-alcoholic fatty liver disease (NAFLD). The chapter ends with specific discussions about the relationships between obesity and other obesity-related diseases, including hypertension, dyslipidemia, atherosclerosis, coronary heart disease and stroke.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kuk JL, Ardern CI. Are metabolically normal but obese individuals at lower risk for all-cause mortality? Diab Care. 2009;32(12):2297–9.

    Article  Google Scholar 

  2. Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:92–103.

    Article  CAS  Google Scholar 

  3. Messer JI, Jackman MR, Willis WT. Pyruvate and citric acid cycle carbon requirements in isolated skeletal muscle mitochondria. Am J Physiol Cell Physiol. 2004;286(3):C565–72.

    Article  CAS  PubMed  Google Scholar 

  4. Hoppeler H, Fluck M. Plasticity of skeletal muscle mitochondria: structure and function. Med Sci Sports Exerc. 2003;35:95–104.

    Article  CAS  PubMed  Google Scholar 

  5. Chomentowski P, Coen PM, Radikova A, Goodpaster BH, Toledo FG. Skeletal muscle mitochondria in insulin resistance: differences in intermyofibrillar versus subsarcolemmal subpopulations and relationship to metabolic flexibility. J Clin Endocrinol Metab. 2011;96:493–503.

    Article  Google Scholar 

  6. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care. 2007;30:89–94.

    Article  CAS  PubMed  Google Scholar 

  7. Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am. 2011;95(5):875–92.

    Article  CAS  PubMed  Google Scholar 

  8. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab. 1998;83:2773–6.

    Article  CAS  PubMed  Google Scholar 

  9. Reaven GM. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diabetes Vasc Dis Res. 2005;2:105–12.

    Article  Google Scholar 

  10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.

    Article  CAS  PubMed  Google Scholar 

  11. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26:3320–5.

    Article  CAS  PubMed  Google Scholar 

  12. Qu H, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB. The definition of insulin resistance using HOMA-IR for American of Mexican descent using machine learning. PLoS ONE. 2011;6(6):e21041.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, Gude F, Garcia F, DeFrancisco A, Quintela AG. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13:47.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Rasmussen-Torvik LJ, Pankow JS, Jacobs DR, Steffen LM, Moran AM, Steinberger J, Sinaiko AR. Heritability and genetic correlations of insulin sensitivity measured by the euglycemic clamp. Diabet Med. 2007;24(11):1286–9.

    Article  CAS  PubMed  Google Scholar 

  15. Staten MA, Stern MP, Miller WG, Steffes MW. Campbell SE for the insulin standardization workgroup. Diabetes Care. 2010;33(1):205–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Johnson JL, Duick DS, Chui MA, Aldasouqi SA. Identifying prediabetes using fasting insulin levels. Endocr Pract. 2010;16(1):47–52.

    Article  PubMed  Google Scholar 

  17. Ter Horst KW, Gilijamse PW, Koopman KE, de Weijer BA, Brands M, Kootte RS, et al. Insulin resistance in obesity can be reliably identified from fasting plasma insulin. Int J Obes. 2015. doi:10.1038/ijo.2015.125.

    Google Scholar 

  18. Haj Mouhamed D, Ezzaher A, Neffati F, Douki W, Gaha L, Najjar MF. Effect of cigarette smoking on insulin resistance risk. Ann Cardiol Angeiol (Paris). 2015. doi:10.1016/j.ancard.2014.12.001.

    Google Scholar 

  19. Scherag A, Jarick I, Grothe J, Biebermann H, Scherag S, Volckmar AL, et al. Investigation of a genome wide association signal for obesity: synthetic association and haplotype analysis at the melanocortin 4 receptor gene locus. PLoS ONE. 2010;5(11):e13967.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Claussnitzer M, Dankel SN, Kyong-Han K, Quon G, Meulemena W, Haugen C, et al. FTO obesity variant circuitry and adipocyte browning in humans. N Engl J Med. 2015. doi:10.1056/NEJMoa1502214.

    PubMed  PubMed Central  Google Scholar 

  22. Li S, Zhao JH, Luan J, Langenberg C, Luben RN, Shaw KT, et al. Genetic predisposition to obesity leads to increased risk of type 2 diabetes. Diabetologia. 2011;54(4):776–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Choquet H, Meyre D. Genetics of obesity: what have we learned? Curr Genomics. 2011;12:169–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ahmad T, Lee IM, Pare G, Chasman DI, Rose L, Ridker PM, Mora S. Lifestyle interaction with fat mass and obesity-associated (FTO) genotype and risk of obesity in apparently healthy U.S. women. Diabetes Care. 2011;34(3):675–80.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Li S, Zhao JH, Luan J, Ekelund U, Luben RN, Khaw KT, et al. Physical activity attenuates the genetic predisposition to obesity in 20,000 men and women from EPIC-Norfolk prospective population study. PLoS Med. 2010;7(8):e1000332.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Paneni F, Costantino S, Cosentino F. Role of oxidative stress in endothelial insulin resistance. World J Diabetes. 2015;6(2):326–32.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA. 2006;103:2653–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Chan DC. Fusion and fission: interlinked processes critical for mitochondrial health. Ann Rev Genet. 2012;46:265–87.

    Article  CAS  PubMed  Google Scholar 

  29. Cheng Z, Almeida FA. Mitochondrial alternation in type 2 diabetes and obesity. Cell Cycle. 2014;13(6):890–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Toledo FG, Goodpaster BH. The role of weight loss and exercise in correcting skeletal muscle mitochondrial abnormalities in obesity, diabetes and aging. Mol Cell Endocrinol. 2013;379:30–4.

    Article  CAS  PubMed  Google Scholar 

  31. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia. Diabetes Care. 2008;31(2):S262–8.

    Article  CAS  PubMed  Google Scholar 

  32. Sleigh A, Raymond-Barker P, Thackray K, Porter D, Hatunic M, Vottero A, Burren C, Mitchell C, McIntyre M, Brage S, et al. Mitochondrial dysfunction in patients with primary congenital insulin resistance. J Clin Invest. 2011;121:2457–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zheng LD, Linarelli LE, Longhua L, Wall SS, Greenawald MH, Seidel RW, et al. Insulin resistance is associated with epigenetic and genetic regulation of mitochondrial DNA in obese humans. Clin Epigentics. 2015. doi:10.1186/s13148-015-0093-1.

    Google Scholar 

  34. Sookoian S, Rosselli MS, Gemma C, Burgueno AL, Fernandez Gianotti T, Castano GO, Pirola CJ. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter. Hepatology. 2010;52:1992–2000.

    Article  CAS  PubMed  Google Scholar 

  35. Barres R, Yan J, Egan B, Treebak JT, Rasmussen M, Fritz T, Caidahl K, Krook A, O’Gorman DF, Zierath JR. Acute exercise remodels promoter methylation in human skeletal muscle. Cell Metab. 2012;15:405–11.

    Article  CAS  PubMed  Google Scholar 

  36. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9:191–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Papaetis GS, Papakyriakou P, Panagiotou TN. Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns. Arch Med Sci. 2014;11(2):463–82.

    Google Scholar 

  38. Pedersen DJ, Guilherme A, Danai LV, Heyda L, Matevossian A, Cohen J, et al. A major role of insulin in promoting obesity-associated adipose tissue inflammation. Mol Metab. 2015;4:507–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Prately R, Zinman B. Impaired fasting glucose and impaired glucose tolerance. Diabetes Care. 2007;30(3):753–9.

    Article  CAS  PubMed  Google Scholar 

  40. Zhang Y, Hu G, Zhang L, Mayo R, Chen L. A novel testing model for opportunistic screening of pre-diabetes and diabetes among U.S. adults. PLoS ONE. 2015. doi:10.137/journal.pone.0120382.

    Google Scholar 

  41. Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Lancet. 2012;379(9833):2279–90.

    Article  PubMed  PubMed Central  Google Scholar 

  42. DECODE Study Group. Age-and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care. 2003;26(1):61–9.

    Article  Google Scholar 

  43. Bansal N. Prediabetes diagnosis and treatment: a review. World J Diabetes. 2015;6(2):296–303.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin–sensitive prediabetic subjects. Circulation. 2000;101:975–80.

    Article  CAS  PubMed  Google Scholar 

  45. Bellamy L, Casas JP, Hingorani AD, et al. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373:1773–9.

    Article  CAS  PubMed  Google Scholar 

  46. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol. 1997;146:214–22.

    Article  CAS  PubMed  Google Scholar 

  47. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D’Agostino RB, Wilson BW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30:1219–25.

    Article  CAS  PubMed  Google Scholar 

  48. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med. 2013;368:1613–24.

    Article  CAS  PubMed  Google Scholar 

  49. Pi-Sunyer FX. Weight loss in type 2 diabetic patients. Diabetes Care. 2005;28(6):1526–7.

    Article  PubMed  Google Scholar 

  50. Uranga-Ocio JA, Bastus-Diez S, Delkader-Palacios D, Garcia-Cristobal N, Leal-Garcia A, Abalo-Delgado R. Enteric neuropathy associated to diabetes mellitus. Rev Esp Enferm Dig. 2015;107(6):366–73.

    PubMed  Google Scholar 

  51. Smith D, Williams C, Ferris C. Diagnosis and treatment of chronic gastroparesis and chronic intestinal pseudo-obstruction. Gastroenterol Clin N Am. 2003;32:619–58.

    Article  Google Scholar 

  52. Kopacova M. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16:2978–90.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Chandrasekharan B, Srinivasan S. Diabetes and the enteric nervous system. Neurogastroenterol Motil. 2007;19:951–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Lambadiari V, Triantafyllou K, Dimitriadis GD. Insulin action in muscle and adipose tissue in type 2 diabetes: the significance of blood flow. World J Diabetes. 2015;6(4):626–33.

    PubMed  PubMed Central  Google Scholar 

  55. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607.

    Article  CAS  PubMed  Google Scholar 

  56. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2014;38(1):S8–16.

    Google Scholar 

  57. Parikh RM, Mohan V. Changing definitions of metabolic syndrome. Indian J Endocrinol Metab. 2012;16(1):7–12.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.

    Article  CAS  PubMed  Google Scholar 

  59. Thorpe AA, Schlaich MP. Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J Diabetes Res. 2015. doi:10.1155/2015/241583.

    Google Scholar 

  60. Rinella ME. Nonalcoholic fatty liver disease a systematic review. JAMA. 2015;313(22):2263–73.

    Article  CAS  PubMed  Google Scholar 

  61. Zhang XQ, Xu DF, Yu CH, Chen WX, Li YM. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(7):1768–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non alcoholic fatty liver disease. Clin Biochem. 2015. doi:10.1016/j.clinbiochem.2015.06.023.

    PubMed  Google Scholar 

  63. Buchholz EM, Rathmore SS, Reid KJ, Jones PG, Chan PS, Rich MW, et al. Body mass index and mortality in acute myocardial infarction patients. Am J Med. 2012;125:796–803.

    Article  Google Scholar 

  64. Mullen JT, Moorman DW, Davenport DL. The obesity paradox: body mass index and outcomes in patients undergoing nonbariatric general surgery. Ann Surg. 2009;250:166–72.

    Article  PubMed  Google Scholar 

  65. Migaj J, Prokop E, Straburzynska-Migaj E, Lesiak M, Grajek S, Mitkowski P. Does influence of obesity on prognosis differ in men and women? A study of obesity paradox in patients with acute coronary syndrome. Kardiol Pol. 2015. doi:10.5603/KP.a2015.0087.

    PubMed  Google Scholar 

  66. Banack HR, Kaufman JS. Does selection bias explain the obesity paradox among individuals with cardiovascular disease? Ann Epidemiol. 2015. doi:10.1016/j.annepidem.2015.02.008.

    PubMed  Google Scholar 

  67. Costanzo P, Cleland JGF, Pellicori P, Clark AL, Hepburn D, Kilpatirck ES, et al. The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study. Ann Int Med. 2015;162(9):610–8.

    Article  PubMed  Google Scholar 

  68. Jerant A, Bertakis KD, Franks P. Body mass index and health care utilization in diabetic and nondiabetic individuals. Med Care. 2015. doi:10.1097/MLR.343.

    PubMed  Google Scholar 

  69. Kortelainen MI, Porvari K. Extreme obesity and associated cardiovascular disease verified at autopsy: time trends over 3 decades. Am J Forensic Med Pathol. 2011;32:372–7.

    Article  PubMed  Google Scholar 

  70. Fadini GP, Boscaro E, de Kreutzenberg S, Agostini C, Seeger F, Dimmeler S, et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care. 2010;33:1097–102.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Graziani F, Biasucci LM, Cialdella P, Lizzo G, Giubilato S, Della Bono R, et al. Thromboxane production in morbidly obese subjects. Am J Cardiol. 2011;107:1656–61.

    Article  CAS  PubMed  Google Scholar 

  72. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, McTierman C. J Am Coll Cardiol. 2000;35(3):537–44.

    Article  CAS  PubMed  Google Scholar 

  73. Savage DB, Petersen KF, Shulman GI. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87:507–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Stone NJ, Robinson JG, Lichtenstien AH, Goff DC, Lloyd-Jones DM, Smith SC, et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med. 2014;160:339–43.

    Article  PubMed  Google Scholar 

  75. Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E, editors. Institute of medicine. Clinical guidelines we can trust. Washington, DC: National Academies Press; 2011.

    Google Scholar 

  76. Xu W, Shubina M, Goldberg SI, Turchin A. Body mass index and all-cause mortality in patients with hypertension. Obesity. 2015. doi:10.1002/oby.21129.

    Google Scholar 

  77. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21–8.

    Article  PubMed  Google Scholar 

  78. Bueter M, Ahmed A, Ashrafian H, le Roux CW. Surg Obes Relat Dis. 2009;5(5):615–20.

    Article  PubMed  Google Scholar 

  79. Tanida M, Yamamoto N, Shibamoto T, Rahmouni K. Involvement of hypothalamic AMP-activated protein kinase in leptin-induces sympathetic nerve activation. PLoS ONE. 2013;8(2):e56660.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Greenfield JR. Melanocortin signaling and the regulation of blood pressure in human obesity. J Neuroendocrinol. 2011;23(2):186–93.

    Article  CAS  PubMed  Google Scholar 

  81. Carmichael CY, Wainford RD. Hypothalamic signaling mechanisms in hypertension. Curr Hypertens Rep. 2015;17:39–47.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Hall JE, do Carmo JM, da Silva AA, Wang Z, et al. Obesity-induces hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Soleimani M. Insulin resistance and hypertension: new insights. Kidney Int. 2015;87:497–9.

    Article  PubMed  Google Scholar 

  84. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368(9536):666–78.

    Article  PubMed  Google Scholar 

  85. Schenkeveld L, Magro M, Oemrawsingh RM, Lenzen M, de Jaegere P, Jan van Geuns R, et al. The influence of optimal medical treatment on the “obesity paradox”, body mass index and long-term mortality in patients treated with percutaneous coronary interventions: a prospective cohort study. BMJ Open. 2012;2:e000535.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Luna-Luna M, Medina-Urrutia A, Vargas-Alarcon G, Coss-Rovirosa F, Vargas-Barron J, Perez-Mendez O. Adipose tissue in metabolic syndrome: onset and progression of atherosclerosis. Arch Med Res. 2015. doi:10.1016/j.arcmed.2015.05.007.

    PubMed  Google Scholar 

  87. Di Chiara T, Argano C, Scaglione A, Corrao S, Pinto A, Scaglione R. Circulating adiponectin: a cardiometabolic marker associated with global cardiovascular risk. Acta Cardiol. 2015;70(1):33–40.

    PubMed  Google Scholar 

  88. Berg AH, Scherer PE. Adipose tissue, inflammation and cardiovascular disease. Circ Res. 2005;96:939–49.

    Article  CAS  PubMed  Google Scholar 

  89. Wu X, Zhu B, Fu L, Wang H, Zhou B, Zou S, Shi J. Prevalence, incidence, and mortality of stroke in the Chinese island populations: a systematic review. PLoS ONE. 2013;8:e78629.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin. 2005;21:1693–9.

    Article  PubMed  Google Scholar 

  91. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370–5.

    Article  CAS  PubMed  Google Scholar 

  92. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischemic stroke and bleeding in 182,678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33:1500–10.

    Article  PubMed  Google Scholar 

  93. Hajhosseiny R, Matthews GK, Lip GY. The metabolic syndrome, atrial fibrillation and stroke: tackling an emerging epidemic. Heart Rhythm. 2015. doi:10.1016/j.hrthm.2015.06.038.

    PubMed  Google Scholar 

  94. Liu J, Butler KR, Buxbaum SG, Sung JH, Campbell BW, Taylor HA. Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study. Clin Endocrinol (Oxford). 2010;72:32–7.

    Article  CAS  Google Scholar 

  95. Wang TJ, Parise H, Levy D, D’Agostino RB, Wolf PA, Vasan RS, Benjamin EJ. JAMA. 2004;292(20):2471–7.

    Article  CAS  PubMed  Google Scholar 

  96. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2015. doi:10.1161/Circulationaha.1007.702795.

    Google Scholar 

  97. Hardy CM, Birse RT, Wolf MJ, Yu L, Bodmer R, Gibbs AG. Obesity-associated cardiac dysfunction in starvation-selectee drosophila melanogaster. Am J Physiol Regul Integr Comp Physiol. 2015. doi:10.1152/ajpregu.00160.2015.

    Google Scholar 

  98. Khavandi K, Khavandi A, Asghar O, Greenstein A, Withers S, Heagerty AM, Malik R. Diabetic cardiomyopathy—a distinct disease? Best Pract Res Clin Endocrinol Metab. 2009;23(3):347–60.

    Article  PubMed  Google Scholar 

  99. Waddingham MT, Edgley AJ, Tsuchimochi H, Kelly DJ, Shirai M, Pearson JT. Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy. World J Diabetes. 2015;6(7):943–60.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robin P. Blackstone .

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Blackstone, R.P. (2016). Obesity-Related Diseases and Syndromes: Insulin Resistance, Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Cardiovascular Disease, and Metabolic Syndrome. In: Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-39409-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-39409-1_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-39407-7

  • Online ISBN: 978-3-319-39409-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics